Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Peter J. Ferguson"'
Autor:
Yousef Najajreh, Ronak Zareardalan, Saman Maleki Vareki, Meng Zhang, James Koropatnick, Xiufen Zheng, Mikal El-Hajjar, Rene Figueredo, Peter J. Ferguson, Faizah Alotaibi, Wei-Ping Min, Mateusz Rytelewski
Publikováno v:
European Journal of Immunology. 50:695-704
CD5 is expressed on T cells and a subset of B cells (B1a). It can attenuate TCR signalling and impair CTL activation and is a therapeutic targetable tumour antigen expressed on leukemic T and B cells. However, the potential therapeutic effect of func
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6dd3eb35393748ac87daa025e4898ef
https://doi.org/10.1002/eji.201948309
https://doi.org/10.1002/eji.201948309
Autor:
Saman Maleki Vareki, Di Chen, Christine Di Cresce, Peter J Ferguson, Rene Figueredo, Macarena Pampillo, Mateusz Rytelewski, Mark Vincent, Weiping Min, Xiufen Zheng, James Koropatnick
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0143435 (2015)
Indoleamine 2,3-dioxygenase-1 (IDO) is an immune regulatory enzyme expressed by most human tumors. IDO levels in tumor cells correlate with increased metastasis and poor patient outcome and IDO is linked to tumor cell resistance to immunotherapy, rad
Externí odkaz:
https://doaj.org/article/e30136094b0f4f87a8c34385fcaf3fbd
Autor:
Peter J. Ferguson, Mark D. Vincent, Yousef Najajreh, Brian Shilton, Stephen Ritter, Rima Al-awar, Richard Marcellus, Mohammed Mohammed, Methvin Isaac, James Koropatnick
Publikováno v:
Cancer Research. 82:346-346
The inherent genetic instability of cancer cells and the dependence of many tumor types on oncogenic drivers contribute selectivity of anticancer agents against tumor cells. That selectivity is limited, and toxicity to normal cells remains a major li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a3a5d42c425108a3377f9957aa34fb6
https://doi.org/10.1158/1538-7445.am2022-346
https://doi.org/10.1158/1538-7445.am2022-346
Autor:
Mateusz Rytelewski, Peter J Ferguson, Saman Maleki Vareki, Rene Figueredo, Mark Vincent, James Koropatnick
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 2, Iss C (2013)
A high mutation rate leading to tumor cell heterogeneity is a driver of malignancy in human cancers. Paradoxically, however, genomic instability can also render tumors vulnerable to therapeutic attack. Thus, targeting DNA repair may induce an intoler
Externí odkaz:
https://doaj.org/article/e84208e9380445daa66005f7cd1fbf3b
Autor:
Saman Maleki Vareki, Xiufen Zheng, Meng Zhang, Ronak Zareardalan, Yousef Najajreh, Rene Figueredo, James Koropatnick, Wei-Ping Min, Mateusz Rytelewski, Peter J. Ferguson, Mikal El-Hajjar, Faizah Alotaibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e241679c9d9eccd81c0bc05694b1cf9
https://doi.org/10.1002/eji.201948309/v3/response1
https://doi.org/10.1002/eji.201948309/v3/response1
Autor:
Yousef Najajreh, James Koropatnnick, Rima Al-awar, Richard Marcellus, Stephen Ritter, Methvin Isaac, Brian H. Shilton, M. Vincent, Mohammed Mohammed, Peter J. Ferguson
Publikováno v:
Cancer Research. 81:PO-039
Despite the innovations in chemotherapeutic treatment of pancreatic cancer, the generally poor outcome of this disease begs the search for novel targets. RAD51 is a critical component of homologous recombination DNA repair, binding with BRCA2 and for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40d89a0f6b9a359c20f9d4ebe30eb43b
https://doi.org/10.1158/1538-7445.panca21-po-039
https://doi.org/10.1158/1538-7445.panca21-po-039
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 364:46-54
Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the tumor-selective toxicity of some chemotherapy drugs. This synthetic lethality can be enhanced by inhibitors of DNA repair.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4ce314d1f1a042c5767a95b7ce774fc
https://doi.org/10.1124/jpet.117.241661
https://doi.org/10.1124/jpet.117.241661
Autor:
Faizah, Alotaibi, Mateusz, Rytelewski, Rene, Figueredo, Ronak, Zareardalan, Meng, Zhang, Peter J, Ferguson, Saman, Maleki Vareki, Yousef, Najajreh, Mikal, El-Hajjar, Xiufen, Zheng, Wei-Ping, Min, James, Koropatnick
Publikováno v:
European journal of immunologyReferences. 50(5)
CD5 is expressed on T cells and a subset of B cells (B1a). It can attenuate TCR signalling and impair CTL activation and is a therapeutic targetable tumour antigen expressed on leukemic T and B cells. However, the potential therapeutic effect of func
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::961b5319a0b4575b4817786f76c28e72
https://pubmed.ncbi.nlm.nih.gov/31943150
https://pubmed.ncbi.nlm.nih.gov/31943150
Autor:
James Koropatnick, Saman Maleki Vareki, Rene Figueredo, Meng Zhang, Ronak Zareardalan, Peter J. Ferguson, Yousef Najajreh, Xiufen Zheng, Faizah Alotaibi, Wei-Ping Min, Mateusz Rytelewski, Mikal El-Hajjar
Publikováno v:
Cancer Research. 80:917-917
Blockade of programmed cell death protein 1 (PD-1) is approved for treatment of multiple human cancers and is the focus of multiple studies due to its key role in T cell function. However, only patients with ‘'hot'' tumors (i.e. those with increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c0f32ea3e563e47362fd2dd34fb1a8a
https://doi.org/10.1158/1538-7445.am2020-917
https://doi.org/10.1158/1538-7445.am2020-917
Publikováno v:
Tumori Journal. 102:31-39
Aims and background In light of the need for more selective anticancer therapy, much work has been directed at developing compounds or biological agents that target functions specific to cancer cells. To this end, numerous viruses have been engineere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac35839f0e29239dcddbb414c1e8cdd5
https://doi.org/10.5301/tj.5000438
https://doi.org/10.5301/tj.5000438